Investors Tell 1st Circ. Sarepta Hid FDA Testing Issues
A group of shareholders asked the First Circuit on Monday to revive their securities class action claiming executives at Sarepta Therapeutics Inc. selectively omitted facts and misled investors in 2014 about...To view the full article, register now.
Already a subscriber? Click here to view full article